Strong evidence demonstrates that Kras can regulate ADAM17 activity in a MEK/ERK-dependent manner, inducing a KRAS/ERK/ADAM17 signalling axis constitutively activated in CRC [210]. The gene discussed is KRAS; the disease is colorectal carcinoma.